In vivo vaccination with cell line-derived whole tumor lysates: neoantigen quality, not quantity matters

BACKGROUND: Cancer vaccines provide a complex source of neoantigens. Still, increasing evidence reveals that the neoantigen quality rather than the quantity is predictive for treatment outcome. METHODS: Using the preclinical Mlh1(−/−) tumor model, we performed a side-by side comparison of two autolo...

Descripción completa

Detalles Bibliográficos
Autores principales: Salewski, Inken, Gladbach, Yvonne Saara, Kuntoff, Steffen, Irmscher, Nina, Hahn, Olga, Junghanss, Christian, Maletzki, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7579816/
https://www.ncbi.nlm.nih.gov/pubmed/33087163
http://dx.doi.org/10.1186/s12967-020-02570-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7579816/
https://www.ncbi.nlm.nih.gov/pubmed/33087163
http://dx.doi.org/10.1186/s12967-020-02570-y

Ejemplares similares